(PRVA) Privia Health - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US74276R1023
PRVA: Technology, Tools, Services, Networks, Medical, Care
Privia Health Group Inc (NASDAQ:PRVA) is a national physician-enablement company based in Arlington, Virginia, founded in 2007. It partners with medical groups, health plans, and health systems to enhance physician practices and patient experiences, rewarding doctors for both in-person and virtual care. Their services include technology tools for workflow optimization, management services to reduce administrative burdens, a single-TIN medical group for better payer negotiations, an accountable care organization (ACO) focused on value-based care, and a network connecting providers with payers and new patients.
The companys business model is designed to support independent providers through technology and data analytics, enabling them to focus on patient care. The single-TIN structure aligns financial incentives, crucial for value-based care. Their ACO model emphasizes improving quality metrics and reducing costs, often participating in programs like Medicare Shared Savings. Additionally, their network facilitates custom contracts, enhancing scalability and access to patient populations.
Financially, Privia Health has a market cap of approximately $2.7 billion. The current P/E ratio is high at 204, but the forward P/E of 34 suggests anticipated growth. The P/B ratio of 4.39 indicates a premium valuation relative to book value, while the P/S ratio of 1.57 reflects reasonable revenue generation relative to market cap. These metrics highlight the companys potential for future performance and its position in the healthcare services sector.
Additional Sources for PRVA Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
PRVA Stock Overview
Market Cap in USD | 3,044m |
Sector | Healthcare |
Industry | Health Information Services |
GiC Sub-Industry | Health Care Services |
IPO / Inception | 2021-04-28 |
PRVA Stock Ratings
Growth 5y | -1.82% |
Fundamental | 14.2% |
Dividend | 0.0% |
Rel. Strength Industry | 15.3 |
Analysts | 4.57/5 |
Fair Price Momentum | 23.38 USD |
Fair Price DCF | 16.58 USD |
PRVA Dividends
No Dividends PaidPRVA Growth Ratios
Growth Correlation 3m | 87.6% |
Growth Correlation 12m | 68.1% |
Growth Correlation 5y | -68% |
CAGR 5y | 0.83% |
CAGR/Max DD 5y | 0.01 |
Sharpe Ratio 12m | 0.56 |
Alpha | 7.11 |
Beta | 0.77 |
Volatility | 49.75% |
Current Volume | 618.6k |
Average Volume 20d | 850.4k |
As of March 15, 2025, the stock is trading at USD 23.75 with a total of 618,588 shares traded.
Over the past week, the price has changed by -7.01%, over one month by -5.90%, over three months by +8.60% and over the past year by +16.31%.
Neither. Based on ValueRay Fundamental Analyses, Privia Health is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 14.22 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of PRVA as of March 2025 is 23.38. This means that PRVA is currently overvalued and has a potential downside of -1.56%.
Privia Health has received a consensus analysts rating of 4.57. Therefor, it is recommend to buy PRVA.
- Strong Buy: 15
- Buy: 6
- Hold: 2
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, PRVA Privia Health will be worth about 25.8 in March 2026. The stock is currently trading at 23.75. This means that the stock has a potential upside of +8.46%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 29.6 | 24.6% |
Analysts Target Price | 26 | 9.3% |
ValueRay Target Price | 25.8 | 8.5% |